<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl7" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.015</object-id><label>Table 7.</label><caption><p>Antibiogram of <italic>Acinetobacter</italic> spp. causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.015">http://dx.doi.org/10.7554/eLife.18082.015</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n&#160;=&#160;449 patients)</th><th valign="top">HCAB <break/>(n&#160;=&#160;115 patients)</th><th valign="top">HAB <break/>(n&#160;=&#160;501 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td rowspan="4" valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">112/390 (29%)</td><td valign="top">45/105 (43%)</td><td valign="top">310/455 (68%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Tobramycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Amikacin</td><td valign="top">123/442 (28%)</td><td valign="top">45/112 (40%)</td><td valign="top">310/495 (63%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Netilmicin</td><td valign="top">44/203 (22%)</td><td valign="top">24/64 (38%)</td><td valign="top">224/381 (59%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Antipseudomonal carbapenems</td><td valign="top">Imipenem</td><td valign="top">87/397 (22%)</td><td valign="top">37/102 (36%)</td><td valign="top">293/459 (64%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Meropenem</td><td valign="top">65/284 (23%)</td><td valign="top">32/81 (40%)</td><td valign="top">229/348 (66%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Doripenem</td><td valign="top">16/45 (36%)</td><td valign="top">9/10 (90%)</td><td valign="top">6/7 (86%)</td><td valign="top">0.001</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">84/413 (20%)</td><td valign="top">53/106 (50%)</td><td valign="top">322/481 (67%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Levofloxacin</td><td valign="top">2/5 (40%)</td><td valign="top">2/2 (100%)</td><td valign="top">8/9 (89%)</td><td valign="top">0.11</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal penicillins + &#946; lactamase inhibitors</td><td valign="top">Ticarcillin- clauvanic acid</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Piperacillin-tazobactam</td><td valign="top">22/98 (22%)</td><td valign="top">13/28 (46%)</td><td valign="top">74/106 (70%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Extended-spectrum cephalosporins</td><td valign="top">Cefotaxime</td><td valign="top">242/291 (83%)</td><td valign="top">89/94 (95%)</td><td valign="top">407/420 (97%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ceftazidime</td><td valign="top">133/448 (30%)</td><td valign="top">61/114 (54%)</td><td valign="top">377/500 (75%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefepime</td><td valign="top">18/53 (34%)</td><td valign="top">10/22 (45%)</td><td valign="top">95/133 (71%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Folate pathway inhibitor</td><td valign="top">Trimethopri-sulphamethoxazole</td><td valign="top">119/356 (33%)</td><td valign="top">55/99 (56%)</td><td valign="top">333/435 (77%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Penicillins + &#946; lactamase inhibitors</td><td valign="top">Ampicillin-sulbactam</td><td valign="top">43/134 (32%)</td><td valign="top">16/29 (55%)</td><td valign="top">79/115 (69%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Polymyxins</td><td valign="top">Colistin *</td><td valign="top">2/16 (13%)</td><td valign="top">0/14 (0%)</td><td valign="top">0/33 (0%)</td><td valign="top">0.11</td></tr><tr><td valign="top">Polymyxin B</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="3" valign="top">Tetracyclines</td><td valign="top">Tetracycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Doxycycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Minocycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">125/449 (28%)</td><td valign="top">58/115 (50%)</td><td valign="top">374/501 (75%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn12"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB&#160;=&#160;Community-acquired bacteraemia, HCAB&#160;=&#160;Healthcare-associated bacteraemia, HAB&#160;= Hospital-acquired bacteraemia, and NA&#160;=&#160;Not available. The first isolate of each patient was used. MDR: non-susceptible to &#8805;1 agent in &#8805;3 antimicrobial categories.</p></fn><fn id="tblfn13"><p>* Defined by using an inhibition zone of &lt;11 mm.</p></fn></table-wrap-foot></table-wrap>